ATE340568T1 - Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns - Google Patents

Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns

Info

Publication number
ATE340568T1
ATE340568T1 AT04722501T AT04722501T ATE340568T1 AT E340568 T1 ATE340568 T1 AT E340568T1 AT 04722501 T AT04722501 T AT 04722501T AT 04722501 T AT04722501 T AT 04722501T AT E340568 T1 ATE340568 T1 AT E340568T1
Authority
AT
Austria
Prior art keywords
brain
lactate
potassium
treatment
lactic acid
Prior art date
Application number
AT04722501T
Other languages
English (en)
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Application granted granted Critical
Publication of ATE340568T1 publication Critical patent/ATE340568T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
AT04722501T 2003-05-01 2004-03-22 Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns ATE340568T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (1)

Publication Number Publication Date
ATE340568T1 true ATE340568T1 (de) 2006-10-15

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04722501T ATE340568T1 (de) 2003-05-01 2004-03-22 Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns

Country Status (30)

Country Link
US (1) US20080125488A1 (de)
EP (2) EP1759695A1 (de)
JP (1) JP5037937B2 (de)
KR (1) KR101076059B1 (de)
CN (1) CN1777416B (de)
AR (1) AR043670A1 (de)
AT (1) ATE340568T1 (de)
AU (1) AU2004233904B2 (de)
BR (1) BRPI0409867A (de)
CA (1) CA2523740C (de)
CY (1) CY1105880T1 (de)
DE (1) DE602004002585T2 (de)
DK (1) DK1617834T3 (de)
EA (2) EA013846B1 (de)
ES (1) ES2274438T3 (de)
IL (1) IL171721A (de)
MA (1) MA27845A1 (de)
MX (1) MXPA05011532A (de)
MY (1) MY140382A (de)
NO (1) NO20055652L (de)
NZ (1) NZ543201A (de)
PL (1) PL1617834T3 (de)
PT (1) PT1617834E (de)
SG (1) SG160217A1 (de)
SI (1) SI1617834T1 (de)
TN (1) TNSN05275A1 (de)
TW (1) TWI290045B (de)
UA (1) UA86937C2 (de)
WO (1) WO2004096204A1 (de)
ZA (1) ZA200509684B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007371A4 (de) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd Lactat und calciumhaltige pharmazeutische zusammensetzung und ihre verwendungen
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
KR20120015295A (ko) * 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP4008326A1 (de) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Einwertige metallkationen-trockenpulver zum inhalieren
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
ES2604855T3 (es) * 2012-08-01 2017-03-09 Purac Biochem Bv Polvo de lactato y procedimiento de preparación del mismo
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9557334B2 (en) 2012-10-25 2017-01-31 Run Them Sweet Llc Formulations and methods to provide nutrition to human and other patients
EP2754356A1 (de) 2013-01-15 2014-07-16 Purac Biochem N.V. Verbessertes Herstellungsverfahren für Nisin
EP2769630B1 (de) 2013-02-26 2016-04-27 Purac Biochem N.V. Verbessertes Nisinherstellungsverfahren
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
EP3065729A4 (de) 2013-11-06 2017-05-31 Aeromics, Inc. Neuartige formulierungen
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
EP3481216B2 (de) 2016-07-07 2024-03-06 DSM IP Assets B.V. Verfahren zur herstellung von rapssamenproteinisolat sowie proteinisolat erhalten gemäss dem verfahren
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
EP3920846A4 (de) * 2019-02-06 2022-11-09 The Board and Trustees of the Leland Stanford Junior University Biologisch modifizierte gefässtransplantate für verbesserte ergebnisse in der bypass-chirurgie
US20230113843A1 (en) * 2020-01-24 2023-04-13 Daniel Q. Barkey Compositions and methods for weight loss
CN119013010A (zh) * 2021-12-16 2024-11-22 艾维尔勒斯生物公司 用于治疗慢性肺病的可吸入或可摄入的乳酸组合物
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (de) 2023-07-31 2025-02-05 M2Rlab SL Verfahren zur polarisation von zellen zu einem neuen m2-phänotyp und verwendungen dieser m2-polarisierten zellen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ,リチヤ−ド エル L↓−乳酸および/またはピルビン酸アニオンを用いた流体式治療法
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
PT701455E (pt) * 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
PL1617834T3 (pl) 2007-02-28
TWI290045B (en) 2007-11-21
NO20055652D0 (no) 2005-11-30
JP5037937B2 (ja) 2012-10-03
DK1617834T3 (da) 2007-02-05
KR20050119701A (ko) 2005-12-21
SG160217A1 (en) 2010-04-29
EP1617834A1 (de) 2006-01-25
TW200423923A (en) 2004-11-16
HK1085942A1 (en) 2006-09-08
IL171721A (en) 2012-05-31
AU2004233904A1 (en) 2004-11-11
CN1777416B (zh) 2012-11-07
EA013846B1 (ru) 2010-08-30
TNSN05275A1 (en) 2007-07-10
NZ543201A (en) 2007-05-31
MXPA05011532A (es) 2006-05-31
KR101076059B1 (ko) 2011-10-21
WO2004096204A1 (en) 2004-11-11
CN1777416A (zh) 2006-05-24
ZA200509684B (en) 2007-03-28
DE602004002585D1 (de) 2006-11-09
BRPI0409867A (pt) 2006-05-16
EP1759695A1 (de) 2007-03-07
SI1617834T1 (sl) 2007-02-28
US20080125488A1 (en) 2008-05-29
ES2274438T3 (es) 2007-05-16
CA2523740A1 (en) 2004-11-11
MY140382A (en) 2009-12-31
EA200801073A1 (ru) 2008-08-29
CA2523740C (en) 2012-05-15
AU2004233904B2 (en) 2009-11-12
UA86937C2 (ru) 2009-06-10
JP2006525324A (ja) 2006-11-09
EP1617834B1 (de) 2006-09-27
PT1617834E (pt) 2007-01-31
EA200501675A1 (ru) 2006-06-30
AR043670A1 (es) 2005-08-03
NO20055652L (no) 2006-02-01
MA27845A1 (fr) 2006-04-03
EA010948B1 (ru) 2008-12-30
CY1105880T1 (el) 2011-02-02
DE602004002585T2 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
DE602004002585D1 (de) VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
DE602005026078D1 (de) Verwendung von Antioxidantien zur Verhinderung von Oxidation und zur Reduzierung von Wirkstoffzersetzung in wirkstoffhaltigen medizinischen Artikeln
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE499105T1 (de) Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen
DE602005015451D1 (de) Auf probiotischen bakterien basierende zusammensetzung und ihre verwendung zur vorbeugung und/oder behandlung von atemwegserkrankungen und/oder infektionen sowie zur verbesserung der darmtätigkeit
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE376444T1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
EP4196127C0 (de) Nicotinamid-mononukleotid-derivate zur behandlung und prävention von sichelzellkrankheit
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE602004017613D1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz-superinfektionen und pilz-rezidiven
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
ATE406158T1 (de) Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit
ATE373482T1 (de) Pharmazeutische zusammensetzung zur lokalen behandlung von hauterkrankungen und hautwunden
EP4355320A4 (de) Organonitro- und sulfoxyalkylorganonitroverbindungen zur verwendung bei der behandlung von medizinischen erkrankungen
DE602004019481D1 (de) Antiandrogen-Oligonukleotide zur Behandlung von Androgen-verwandten Hautkrankheiten, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen und deren Verwendung
DE60313208D1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderivate zur behandlung von schmerz oder magen-darm-erkrankungen
EP4183416A4 (de) Mittel zur prävention oder behandlung von muskelerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1617834

Country of ref document: EP